Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes

K. Menghrajani*, Y. Zhang, C. Famulare, S. M. Devlin, M. S. Tallman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK). The population included 40 female (63 %) and 23 male (37 %) patients, with a median age of 51 years old (range 18–82 years). Of the 31 patients who had had an antecedent malignancy, 14 (45 %) had had breast cancer or DCIS and 22 (71 %) had received anthracycline-based systemic chemotherapy. The translocation partner for the 11q23 rearrangement was identified in 60 of the 63 patients (95 %) studied. The distribution of translocation partners differed for those who had previously received cytotoxic chemotherapy. Most patients with therapy-related disease had a 9p22 or 19p13 partner, as compared to those with de novo disease (95 % vs. 68 %, p = 0.023). Of the 30 patients who received all therapy under observation, 15 (50 %) patients had de novo disease and 15 (50 %) had received antecedent chemotherapy. No significant difference in survival was observed between groups (p = 0.44). Twenty-two patients received induction as up-front therapy, of whom 11 (50 %) achieved CR / CRi. The achievement of CR / CRi with one course of induction was associated with improved OS, with a 6-month OS of 73 % as compared to 23 % for those who did not (p = 0.018). The achievement of CR / CRi with a single course of induction may be a marker of favorable survival in this subtype of high-risk AML. Key Point: Response to a single induction was associated with favorable survival in this population.

Original languageEnglish (US)
Article number106453
JournalLeukemia Research
Volume98
DOIs
StatePublished - Nov 2020

Keywords

  • 11q23
  • AML
  • Cytogenetics
  • KMT2A
  • MLL
  • Therapy-related myeloid neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes'. Together they form a unique fingerprint.

Cite this